GGrantIndex
Sort

48,018 grants matching immunotherapy

Developing preclinical xenograft models in zebrafish.

$794,628
David Michael Langenau · Massachusetts General Hospital · R24 · FY2024 · OD

Developing preclinical xenograft models in zebrafish.

$794,628
David Michael Langenau · Massachusetts General Hospital · R24 · FY2023 · OD

Evolution and Function of Immunogenetic Diversity across the Eastern Hemisphere

$794,519
Paul John Norman · University Of Colorado Denver · R01 · FY2022 · AI

Development of Drugs Acting at Adenosine Receptors

$794,513
Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK

Regulation of innate lymphocyte function

$794,415
Eric O Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis

$794,337
Justin M Balko · Vanderbilt University Medical Center · R01 · FY2024 · HL

Strategies for Prevention of Autoimmunity

$794,026
Stanford University · U19 · FY2001 · DK

Metformin for chemoprevention of lung cancer in obese subjects at high risk

$794,005
Saikrishna Yendamuri · Roswell Park Cancer Institute Corp · R01 · FY2023 · CA

Targeting virus-specific CAR T cells to lymphoid follicles to achieve durable HIV suppression

$793,546
Pamela J Skinner · University Of Minnesota · R01 · FY2021 · AI

Engineering knotted peptide therapeutics for pediatric brain tumor patients

$793,459
James M Olson · Fred Hutchinson Cancer Research Center · R01 · FY2020 · CA

Pathogenesis of Hepatitis B Virus in Transgenic Mice

$792,726
Francis Vincent Chisari · Scripps Research Institute, The · R01 · FY2008 · CA

NK/DC Cross-Talk and Antiviral Response

$792,714
Luis J. Montaner · Wistar Institute · R01 · FY2010 · AI

Data-driven inference of regulators for cytokine-mediated tumor killing

$792,649
Peng Jiang · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Development of botulinum neurotoxin immunotherapy

$792,374
James D. Marks · University Of California, San Francisco · U01 · FY2007 · AI

NP855 for Targeting Thyrointegrin αvβ3 receptors and Norepinephrine Transporter in Neuroblastoma Management

$792,367
Paul Davis · Nanopharmaceuticals, Llc · R44 · FY2024 · CA

MHC Variation in Host Response to SARS-CoV2 and COVID-19 Outcomes

$791,948
Jill Allison Hollenbach · University Of California, San Francisco · R01 · FY2023 · AI

Clinical Protocol and Data Management

$791,885
Vicki Leigh Keedy · Vanderbilt University Medical Center · P30 · FY2020 · CA

Clinical Protocol and Data Management

$791,885
Elizabeth J Davis · Vanderbilt University Medical Center · P30 · FY2023 · CA

Clinical Protocol and Data Management

$791,885
Elizabeth J Davis · Vanderbilt University Medical Center · P30 · FY2024 · CA

Clinical Protocol and Data Management

$791,885
Vicki Leigh Keedy · Vanderbilt University Medical Center · P30 · FY2021 · CA

Clinical Protocol and Data Management

$791,885
Elizabeth J Davis · Vanderbilt University Medical Center · P30 · FY2022 · CA

3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoir

$791,861
Marina Caskey · Rockefeller University · U01 · FY2019 · AI

Receptor Mediated T and B Cell Activation

$791,759
Richard J. Hodes · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Persistent Immunogenicity of IDLV delivering Gag and membrane tethered HIV-1 Envelope Trimers

$791,661
Maria Blasi · Duke University · R01 · FY2025 · AI

Effects of systemic and topical perturbations on human microbes

$791,525
Heidi Kong · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2022 · AR